Immunovant Inc (NASDAQ:IMVT) has a beta value of 0.81 and has seen 0.6 million shares traded in the recent trading session. The company, currently valued at $2.83B, closed the recent trade at $16.68 per share which meant it lost -$0.41 on the day or -2.37% during that session. The IMVT stock price is -106.65% off its 52-week high price of $34.47 and -0.24% below the 52-week low of $16.72. If we look at the company’s 10-day average daily trading volume, we find that it stood at 2.79 million shares traded. The 3-month trading volume is 1.49 million shares.
The consensus among analysts is that Immunovant Inc (IMVT) is Buy stock at the moment, with a recommendation rating of 1.29. 1 analysts rate the stock as a Sell, while 0 rate it as Overweight. 6 out of 20 have rated it as a Hold, with 13 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.72.
Immunovant Inc (NASDAQ:IMVT) trade information
Sporting -2.37% in the red today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the IMVT stock price touched $16.68 or saw a rise of 12.03%. Year-to-date, Immunovant Inc shares have moved -32.64%, while the 5-day performance has seen it change -8.27%. Over the past 30 days, the shares of Immunovant Inc (NASDAQ:IMVT) have changed -9.52%. Short interest in the company has seen 15.8 million shares shorted with days to cover at 14.8.
Wall Street analysts have a consensus price target for the stock at $49, which means that the shares’ value could jump 65.96% from the levels at last check today. The projected low price target is $5.0 while the price target rests at a high of $57.0. In that case, then, we find that the latest price level in today’s session is -241.73% off the targeted high while a plunge would see the stock lose 70.02% from the levels at last check today.
Immunovant Inc (IMVT) estimates and forecasts
The company’s shares have lost -40.45% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 0.00%. Earnings growth for 2025 is a modest -49.95% while over the next 5 years, the company’s earnings are expected to decrease by -21.29%.
IMVT Dividends
Immunovant Inc is expected to release its next earnings report on 2025-May-29 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Immunovant Inc (NASDAQ:IMVT)’s Major holders
Insiders own 58.08% of the company shares, while shares held by institutions stand at 49.64% with a share float percentage of 118.41%. Investors are also buoyed by the number of investors in a company, with Immunovant Inc having a total of 268.0 institutions that hold shares in the company. The top two institutional holders are FMR LLC with over 10.48 million shares worth more than $276.77 million. As of 2024-06-30, FMR LLC held 7.1765% of shares outstanding.
The other major institutional holder is VANGUARD GROUP INC, with the holding of over 6.51 million shares as of 2024-06-30. The firm’s total holdings are worth over $171.86 million and represent 4.7138% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund. As of Jan 31, 2025, the former fund manager holds about 2.20% shares in the company for having 3.74 shares of worth $63.22 million while later fund manager owns 2.08 shares of worth $35.07 million as of Dec 31, 2024, which makes it owner of about 1.22% of company’s outstanding stock.